Results 181 to 190 of about 57,674 (258)

Oseltamivir drug‐disease modelling in infants with influenza virus infection

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang, David W. Kimberlin, Richard J. Whitley, Edward P. Acosta, For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group   +4 more
wiley   +1 more source

Impact of antimicrobial exposure on bronchoscopy yields in immunocompromised patients: a single-centre experience. [PDF]

J Thorac Dis
Teng A, Tan D, Saripalli KR, Toh T, Puan Y, Chua BLW, Fong I, Gan EMJ, Tan YH.   +8 more
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus, Johaina Sarrage, Hilde Samdal, François Montastruc, Elena Rocca   +4 more
wiley   +1 more source

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

Biopharmaceutics &Drug Disposition, EarlyView.
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula, Jeevan Sai Kallam, Aarika Kanukolanu, Ganesh Korada, Lakshmi Vineela Nalla   +4 more
wiley   +1 more source

Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus. [PDF]

Sci Adv
Valkner CJ, Gibes N, Xie MS, Nair S, Kumar S, Francis S, Venkatakrishnan B, Tsvetkova I, Patterson A, VanNieuwenhze M, Dragnea B, Wang JC, Zlotnick A.   +12 more
europepmc   +1 more source

Modernising antiviral drug discovery: harnessing medicinal plants through machine learning and metabolomics to target the SARS-CoV-2 main protease. [PDF]

In Silico Pharmacol
Msobo A, Maphari PW, Koorsen G, Singab ANB, Mhlongo MI.   +4 more
europepmc   +1 more source

Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye. [PDF]

Turk J Gastroenterol
Gunduz A, Öztoprak NÇ, Sarı ND, Kurtaran B, Önlen Y, Senates E, Zerdali E, Karsen H, Batırel A, Ali RK, Güner R, Yamazhan T, Kose S, Erben N, Ince N, Köksal İ, Sarıgül Yıldırım F, Yoruk G, Komur S, Bal T, Kaya S, Esen Ş, Günal Ö, Yıldız IE, Inan D, Barut Ş, Namıduru M, Tosun S, Türker K, Sener A, Hızel K, Baykam N, Duygu F, Akıncı E, Can G, User U, Gül HC, Akbulut A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F, Hep-C Turkey Study Group.   +44 more
europepmc   +1 more source

A Conversation with Sumit Chanda, Antiviral Drug Discovery Scientist. [PDF]

ACS Cent Sci
Walsh E.
europepmc   +1 more source